Evidence map›Paper›PMID 26010871›Full record

ArticlePloS one2015

Death Receptor-Induced Apoptosis Signalling Regulation by Ezrin Is Cell Type Dependent and Occurs in a DISC-Independent Manner in Colon Cancer Cells.

Elisabetta Iessi, Luciana Zischler, Aurélie Etringer, Marion Bergeret, Aymeric Morlé, Guillaume Jacquemin, Alexandre Morizot, Sarah Shirley, Najoua Lalaoui, Selene L Elifio-Esposito and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Elisabetta IessiINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France.
Luciana ZischlerINSERM, U866, Dijon, F-21079, France; Pós-graduação em Ciências da Saúde, Escola de Medicina, Pontifícia Universidade Católica do Paraná, 80215-901, Curitiba, Paraná, Brazil.
Aurélie EtringerINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France.
Marion BergeretINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France.
Aymeric MorléINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France.
Guillaume JacqueminINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France.
Alexandre MorizotINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France.
Sarah ShirleyINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France.
Najoua LalaouiINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France.
Selene L Elifio-EspositoPós-graduação em Ciências da Saúde, Escola de Medicina, Pontifícia Universidade Católica do Paraná, 80215-901, Curitiba, Paraná, Brazil.
Stefano FaisDepartment of Therapeutic Research and Medicines Evaluation, Antitumor Drugs Section, Istituto Superiore di Sanita, Viale Regina Elena, Rome, Italy.
Carmen GarridoINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France; Centre Georges-François Leclerc, Dijon, F-21000, France.
Eric SolaryINSERM, U1009, Villejuif, F-94805, France; Institut Gustave Roussy, Univ. Paris XI, Villejuif, F-94805, France.
Olivier MicheauINSERM, U866, Dijon, F-21079, France; UFR des Sciences de Santé, Univ. Bourgogne, Dijon, F-21079, France; Centre Georges-François Leclerc, Dijon, F-21000, France.
Université de Bourgogne · FRInserm · FRPontifícia Universidade Católica do Paraná · BRCentre Georges François Leclerc · FRInstitut Gustave Roussy · FRIstituto Superiore di Sanità · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ezrin belongs to the ERM (ezrin-radixin-moesin) protein family and has been demonstrated to regulate early steps of Fas receptor signalling in lymphoid cells, but its contribution to TRAIL-induced cell death regulation in adherent cancer cells remains unknown. In this study we report that regulation of FasL and TRAIL-induced cell death by ezrin is cell type dependant. Ezrin is a positive regulator of apoptosis in T-lymphoma cell line Jurkat, but a negative regulator in colon cancer cells. Using ezrin phosphorylation or actin-binding mutants, we provide evidence that negative regulation of death receptor-induced apoptosis by ezrin occurs in a cytoskeleton- and DISC-independent manner, in colon cancer cells. Remarkably, inhibition of apoptosis induced by these ligands was found to be tightly associated with regulation of ezrin phosphorylation on serine 66, the tumor suppressor gene WWOX and activation of PKA. Deficiency in WWOX expression in the liver cancer SK-HEP1 or the pancreatic Mia PaCa-2 cell lines as well as WWOX silencing or modulation of PKA activation by pharmacological regulators, in the colon cancer cell line SW480, abrogated regulation of TRAIL signalling by ezrin. Altogether our results show that death receptor pro-apoptotic signalling regulation by ezrin can occur downstream of the DISC in colon cancer cells.

Indexed as

ApoptosisSignal TransductionCell Line, TumorColonic NeoplasmsCytoskeletal ProteinsEzrinfas ReceptorHumansMitochondriaOxidoreductasesPhosphorylationPhosphoserineReceptors, Death DomainTNF-Related Apoptosis-Inducing LigandTumor Suppressor ProteinsWW Domain-Containing OxidoreductaseCytoskeletal ProteinsEzrinFAS protein, humanfas ReceptorOxidoreductasesPhosphoserineReceptors, Death DomainTNF-Related Apoptosis-Inducing LigandTumor Suppressor ProteinsWW Domain-Containing OxidoreductaseWWOX protein, human

Identifiers

PMID26010871
PMCPMC4444253
OpenAlexW1468904658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.